Efficacy and Safety of Sequenced Bcma-Directed Therapies in Relapsed/Refractory Multiple Myeloma - a Retrospective, Multicenter, International Cohort Study (SEQ-BCMA Study) (IMS 2026) - Sep 11, 2026 - Abstract #PA-169; Pres time: Sep 25, 2026; "The four most frequent sequences were CAR T→bsAb (72, 40%), ADC→bsAb (29, 16%), CAR T→CAR T (ide cel→cilta cel, 26, 14%), and ADC→CAR T (25, 14%)...2 nd BCMA-Tx was not affected by the time between 1 st and 2 nd BCMA-Tx (6 mo; p=0.42) or intervening talquetamab (p=0.35)... Repeated BCMA-Tx yields high response rates with manageable toxicity, but PFS differs by sequence: CAR T→CAR T provides superior PFS compared to CAR T→bsAb but is attenuated after bsAb. ADC → CAR T appears less detrimental than bsAb→CAR T, though inferior to CAR T→CAR T. These data support CAR T before bsAb and highlight CAR T→bsAb as an unmet need."
Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia
|
|
Christoph Schaefers1; Max Steinhardt2; Emilie Skerbek3; Jan Frenking4; Tim Richardson5; Raphael Teipel6; Mathias Hänel7; Christian Michel8; Maria Dampmann9; Evgenii Shumilov10; Markus Maulhardt11; Abstracts 23rd International Myeloma Society Annual Meeting September 2026 S141 Thomas Pabst12; Wolfgang Willenbacher13; Thomas Melchardt14; Irene Strassl15; Dominik Heim16; Igor Wolfgang Blau17; Jan Vorwerk18; Annamaria Brioli19; Caroline Cichin-Sain20; Sebastian Theurich21; Maximilian Merz22; Katja Weisel1; Leo Rasche23; Lisa B. Leypoldt1
|